RT Journal Article
SR Electronic
T1 SARS-CoV-2 Uses CD4 to Infect T Helper Lymphocytes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.25.20200329
DO 10.1101/2020.09.25.20200329
A1 Brunetti, Natália S.
A1 Davanzo, Gustavo G.
A1 de Moraes, Diogo
A1 Ferrari, Allan J. R.
A1 de Souza, Gabriela F.
A1 Muraro, Stefanie P.
A1 Knittel, Thiago L.
A1 Boldrini, Vinícius O.
A1 Monteiro, Lauar B.
A1 Virgilio-da-Silva, João Victor
A1 Profeta, Gerson S.
A1 Wassano, Natália S.
A1 Santos, Luana N.
A1 Carregari, Victor C.
A1 Dias, Artur H. S.
A1 Veras, Flavio P.
A1 Tavares, Lucas A.
A1 Forato, Julia
A1 Castro, Ícaro
A1 Silva-Costa, Lícia C.
A1 Palma, Andre
A1 Mansour, Eli
A1 Ulaf, Raisa G.
A1 Bernardes, Ana F.
A1 Nunes, Thyago A.
A1 Ribeiro, Luciana C.
A1 Agrela, Marcus V.
A1 Moretti, Maria Luiza
A1 Buscaratti, Lucas I.
A1 Crunfli, Fernanda
A1 Ludwig, Raissa G.
A1 Gerhardt, Jaqueline A.
A1 Munhoz-Alves, Natália
A1 Marques, Ana M.
A1 Sesti-Costa, Renata
A1 Amorim, Mariene R.
A1 Texeira, Daniel A. T.
A1 Parise, Pierina L.
A1 Martini, Matheus C.
A1 Bispo-dos-Santos, Karina
A1 Simeoni, Camila L.
A1 Granja, Fabiana
A1 Silvestrini, Virginia C.
A1 de Oliveira, Eduardo B.
A1 Faça, Vitor M.
A1 Carvalho, Murilo
A1 Castelucci, Bianca G.
A1 Pereira, Alexandre B.
A1 Coimbra, Laís D.
A1 Dias, Marieli M. G.
A1 Rodrigues, Patricia B.
A1 S. P. Gomes, Arilson Bernardo
A1 Pereira, Fabricio B.
A1 Santos, Leonilda M. B.
A1 Bloyet, Louis-Marie
A1 Stumpf, Spencer
A1 Pontelli, Marjorie C.
A1 Whelan, Sean P. J.
A1 Sposito, Andrei C.
A1 Carvalho, Robson F.
A1 Vieira, Andre S.
A1 Vinolo, Marco A. R.
A1 Damasio, André
A1 Velloso, Licio A.
A1 M. Figueira, Ana Carolina
A1 da Silva, Luis L. P.
A1 Cunha, Thiago M.
A1 Nakaya, Helder I.
A1 Marques-Souza, Henrique
A1 Marques, Rafael E.
A1 Martins-de-Souza, Daniel
A1 Skaf, Munir S.
A1 Proença-Modena, José Luiz
A1 Moraes-Vieira, Pedro M.
A1 Mori, Marcelo A.
A1 Farias, Alessandro S.
YR 2023
UL http://medrxiv.org/content/early/2023/01/11/2020.09.25.20200329.abstract
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent of a major global outbreak of respiratory tract disease known as coronavirus disease-2019 (COVID-19). SARS-CoV-2 infects mainly lungs and may cause several immune-related complications, such as lymphocytopenia and cytokine storm, which are associated with the severity of the disease and predict mortality1,2. The mechanism by which SARS-CoV-2 infection may result in immune system dysfunction is still not fully understood. Here we show that SARS-CoV-2 infects human CD4+ T helper cells, but not CD8+ T cells, and is present in blood and bronchoalveolar lavage T helper cells of severe COVID-19 patients. We demonstrated that SARS-CoV-2 spike glycoprotein (S) directly binds to the CD4 molecule, which in turn mediates the entry of SARS-CoV-2 in T helper cells. This leads to impaired CD4 T cell function and may cause cell death. SARS-CoV-2-infected T helper cells express higher levels of IL-10, which is associated with viral persistence and disease severity. Thus, CD4-mediated SARS-CoV-2 infection of T helper cells may contribute to a poor immune response in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from FAEPEX-UNICAMP (#2295/20, #2458/20, #2266/20 and #2274/20), Sao Paulo Research Foundation (FAPESP) (#2019/16116-4, #2019/06372-3, #2020/04583-4, #2013/08293-7, #2020/04579-7, #2015/15626-8, #2018/14933-2, #2020/04746-0, #2019/00098-7, #2020/04919-2, #2017/01184-9), the National Institute of Science and Technology in Neuroimmunomodulation (INCT-NIM) (#465489/2014-1) and FINEP (#01.20.0003.00). A.S.F. and M.A.M. were supported by CNPq productivity awards (#306248/2017-4 and #310287/2018-9). A.J.R.F, G.G.D., A.C.C., N.S.B., L.B.M., F.C., V.C.C., A.B., T.L.K, G.S.P., R.G.L. were supported by FAPESP fellowships (#2019/17007-4, #2019/22398-2, #2019/05155-9, #2019/06459-1, #2019/04726-2, #2017/23920-9, #2016/24163-4, #2016/23328-0). V.O.B. and L.N.S. were supported by FAEPEX fellowship (#2295/20 and #2319/20). D.M. was supported by CAPES fellowship. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study was approved by the University of Campinas Committee for Ethical Research (CAAE number 32078620.4.0000.5404). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are storage in the university databank and will be provided under reasonable request.